Mo1570: EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

An Outtier(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Ganel Schops(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Édouard Louis(Centre Hospitalier Universitaire de Liège), Séverine Vermeire(KU Leuven), João Sabino(KU Leuven), Olivier Dewit
Gastroenterology
May 1, 2022
10.1016/s0016-5085(22)61942-5
Cited by 3

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k